Affinity Asset Advisors’s NextCure NXTC Stock Holding History

Affinity Asset Advisors’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.46M	Buy	291,960 +250,000	+596%	+$1.39M	0.06%	114
2026 Q2	$67.1K	Sell	41,960 -199,866	-83%	-$1.48M	﹤0.01%	111
2026 Q1	$2.58M	Sell	241,826 -5,468	-2%	-$66.8K	0.13%	90
2025 Q4	$3.51M	Buy	247,294 +55,412	+29%	+$574K	0.2%	70
2025 Q3	$1.12M	Sell	191,882 -1	-0%	-$5	0.1%	83
2025 Q2	$1.06M	Hold	191,883	–	–	0.14%	69
2025 Q1	$1.11M	Hold	191,883	–	–	0.11%	81
2024 Q4	$1.78M	Hold	191,883	–	–	0.24%	60
2024 Q3	$3.15M	Buy	191,883 +51,220	+36%	+$943K	0.43%	53
2024 Q2	$2.68M	Buy	140,663 +27,410	+24%	+$533K	0.31%	59
2024 Q1	$3.03M	Buy	+113,253	New	+$1.95M	0.38%	65

Other funds holding NXTC

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Verition Fund Management Greenwich, Connecticut $18B AUM 27.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Pfizer New York $164M AUM 53.62% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Affinity Asset Advisors's NXTC Position: Q3 2026 in Review

Affinity Asset Advisors increased its NextCure (NXTC) stake by 596% in Q3 2026, buying an estimated $1.39M and bringing the position to 291,960 shares worth $1.46M. The position accounts for 0.06% of the portfolio, ranked #114.

Affinity Asset Advisors first reported a position in NXTC in Q1 2024 and has held it in 11 quarters since. The position peaked at $3.51M in Q4 2025. 21 funds tracked by Wall St. Rank hold NXTC as of Q3 2026.

Affinity Asset Advisors held 291,960 shares of NextCure worth $1.46M as of Q3 2026.
Affinity Asset Advisors bought 250,000 NextCure shares in Q3 2026, an estimated $1.39M.
NextCure made up 0.06% of Affinity Asset Advisors's portfolio in Q3 2026, its #114 holding.
Affinity Asset Advisors first reported a position in NextCure in Q1 2024 and has held it in 11 quarters since.
Affinity Asset Advisors's NextCure position peaked at $3.51M in Q4 2025.
21 funds tracked by Wall St. Rank held NextCure as of Q3 2026.

Based on Affinity Asset Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.